Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice

The global prevalence of metabolic syndrome had created one of the most pressing public health dilemmas and significant financial burden to the healthcare system. Despite the surge of glucagon-like peptide-1 agonists, recent studies showed that 40 % of body weight loss is due to lean mass loss, rais...

Descripción completa

Detalles Bibliográficos

Autores principales:	Syed Tareq, Heba A. Ewida, Sumaih Zoubi, Harrison Benson, Dhavalkumar Patel, Hanin Diab, Souvik Patra, Daniela Redrovan, Ehsan Nozohouri, Taysa Berivan Bassani, Alisson Campos Cardoso, Kofi Frimpong-Manson, Lida Khodavirdilou, Md Tareq Aziz, Jenny L. Wilkerson, Jonathan Thompson, Ulrich Bickel, Prasanth K. Chelikani, Ayman Farag, Mahmoud Salama Ahmed
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2025-09-01
Colección:	Pharmacological Research
Materias:	Metabolic syndrome Insulin resistance Obesity EphB tyrosine kinase Metabolism
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S1043661825003251
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!